Efgartigimod (FcRn) — Topline data
H2 2026
Thyroid eye disease (TED): Zai Lab partner argenx to provide topline results from two registrational UplighTED studies in the second half of 2026.Source filing
ZLAB biotech catalysts & pipeline
ZAI LAB LTD · Data as of 2026-10-25
Upcoming catalysts
ZL-1311 — IND submission
Late 2026
• Submit an IND application in the U.S. by year-end 2026 and initiate a global Phase 1 study in the first half of 2027.Source filing
ZL-1503 (IL-13/IL-31R) — Initial data
Q4'26
ZL-1503 (IL-13/IL-31Rα) ZL-1503 Mod-to-Sev AD ● Data (SAD, healthy volunteers) Q4'26Source filing
Povetacicept (APRIL/BAFF) — PDUFA
Nov 30
In June 2026, Zai Lab partner Vertex announced that the FDA accepted its BLA submission for pove for accelerated approval in adults with immunoglobulin A nephropathy (IgAN), with a PDUFA target action date of November 30, 2026.Source filing
elegrobart — Topline data
2027
• Zai Lab to provide topline results from the China Phase 3 registrational study in 2027.Source filing
ZL-1222 (PD-1 / IL-12) — IND submission
2027
• Submit an IND application in the U.S. and initiate a global Phase 1 study in 2027.Source filing
ZL-1503 (IL-13/IL-31R) — Initial data
1H'27
Data (MAD, atopic dermatitis) 1H'27Source filing
ZL-6201 — Topline data
H1 2027
• Provide topline results from the dose escalation portion of the global Phase 1a/b study evaluating ZL-6201 in patients with sarcoma and selected tumors in the first half of 2027.Source filing
zocilurtatug pelitecan — Clinical data readout
2H'27
Programs (Target) Indication IND- enabling Ph 1 PoC Reg/ Ph 3 Status / Next Update Zoci (DLL3 ADC) Zoci 2L+ SCLC ● Data (interim analysis) 2H'27Source filing
zocilurtatug pelitecan — Conference presentation
Oct 23–Oct 27
Global Phase 1 data for zocilurtatug pelitecan (zoci) in combination with a PD-L1 inhibitor in first-line SCLC to be presented at ESMO 2026; planned initiation of a registrational Phase 3 study later this yearSource filing
ZL-1503 (IL-13/IL-31R) — Conference presentation
Nov 12–Nov 16
Findings from the Phase 1/1b first-in-human trial in healthy volunteers (NCT07235384) to be shared at ACAAI 2026 will include pharmacokinetic data following single-dose administration, as well as pharmacodynamic data on AD-related biomarkers across a range of ZL-1503 doses.Source filing